Direct intranigral administration of an ubiquitin proteasome system inhibitor in rat: Behavior, positron emission tomography, immunohistochemistry

Experimental Neurology

Volumn 247, Issue , 2013, Pages 19-24

  Mackey, Scott ^a,d   Jing, Yu ^b,d   Flores, Joseph ^c,d   Dinelle, Katie ^d   Doudet, Doris J ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DALIAN MEDICAL UNIVERSITY   (China)

^c LUND UNIVERSITY   (Sweden)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Cell counting; Lactacystin; Parkinson's disease; Positron emission tomography; Rat; Ubiquitin proteasome system

Indexed keywords

LACTACYSTIN; TRACER; TYROSINE 3 MONOOXYGENASE; VESICULAR MONOAMINE TRANSPORTER 2;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN RADIOGRAPHY; CELL COUNT; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE SEVERITY; DOPAMINERGIC NERVE CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; ISOTOPE LABELING; MALE; MONOAMINE NERVE CELL; MOTOR DYSFUNCTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA; VENTRAL TEGMENTUM;

CELL COUNTING; LACTACYSTIN; PARKINSON'S DISEASE; POSITRON EMISSION TOMOGRAPHY; RAT; UBIQUITIN PROTEASOME SYSTEM;

ACETYLCYSTEINE; ANALYSIS OF VARIANCE; ANIMALS; CARBON ISOTOPES; CELL COUNT; CORPUS STRIATUM; CYSTEINE PROTEINASE INHIBITORS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FUNCTIONAL LATERALITY; HINDLIMB; LOCOMOTION; MOVEMENT DISORDERS; POSITRON-EMISSION TOMOGRAPHY; RATS; RATS, SPRAGUE-DAWLEY; SUBSTANTIA NIGRA; TETRABENAZINE; TIME FACTORS; TYROSINE 3-MONOOXYGENASE;

EID: 84876730225     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2013.03.021     Document Type: Article

References (46)

1. Ahn T.B., Jeon B.S. Protective role of heat shock and heat shock protein 70 in lactacystin-induced cell death both in the rat substantia nigra and PC12 cells. Brain Res. 2006, 1087:159-167.
2. Blandini F., Sinforiani E., Pacchetti C., Samuele A., Bazzini E., Zangaglia R., Nappi G., Martignoni E. Peripheral proteasome and caspase activity in Parkinson disease and Alzheimer disease. Neurology 2006, 66:529-534.
3. Braak H., Del Tredici K., Rub U., de Vos R.A., Jansen Steur E.N., Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 2003, 24:197-211.
4. Cepeda I.L., Flores J., Cornfeldt M.L., O'Kusky J.R., Doudet D.J. Human retinal pigment epithelial cell implants ameliorate motor deficits in two rat models of Parkinson disease. J. Neuropathol. Exp. Neurol. 2007, 66:576-584.
5. Chu Y., Dodiya H., Aebischer P., Olanow C.W., Kordower J.H. Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions. Neurobiol. Dis. 2009, 35:385-398.
6. Ciechanover A. Intracellular protein degradation: from a vague idea thru the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting. Hematol. Am. Soc. Hematol. Educ. Program 2006, 1-12:505-506.
7. Ciechanover A., Brundin P. The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg. Neuron 2003, 40:427-446.
8. Ferrucci M., Pasquali L., Ruggieri S., Paparelli A., Fornai F. Alpha-synuclein and autophagy as common steps in neurodegeneration. Parkinsonism Relat. Disord. 2008, 14(Suppl. 2):S180-S184.
9. Fornai F., Lenzi P., Gesi M., Ferrucci M., Lazzeri G., Busceti C.L., Ruffoli R., Soldani P., Ruggieri S., Alessandri M.G., Paparelli A. Fine structure and biochemical mechanisms underlying nigrostriatal inclusions and cell death after proteasome inhibition. J. Neurosci. 2003, 23:8955-8966.
10. Innis R.B., Cunningham V.J., Delforge J., Fujita M., Gjedde A., Gunn R.N., Holden J., Houle S., Huang S.C., Ichise M., Iida H., Ito H., Kimura Y., Koeppe R.A., Knudsen G.M., Knuuti J., Lammertsma A.A., Laruelle M., Logan J., Maguire R.P., Mintun M.A., Morris E.D., Parsey R., Price J.C., Slifstein M., Sossi V., Suhara T., Votaw J.R., Wong D.F., Carson R.E. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J. Cereb. Blood Flow Metab. 2007, 27:1533-1539.
11. Jewett D.M., Kilbourn M.R., Lee L.C. A simple synthesis of [11C]dihydrotetrabenazine (DTBZ). Nucl. Med. Biol. 1997, 24:197-199.
12. Kim J.S., Lee J.S., Im K.C., Kim S.J., Kim S.Y., Lee D.S., Moon D.H. Performance measurement of the microPET focus 120 scanner. J. Nucl. Med. 2007, 48:1527-1535.
13. Kordower J.H., Kanaan N.M., Chu Y., Suresh Babu R., Stansell J., Terpstra B.T., Sortwell C.E., Steece-Collier K., Collier T.J. Failure of proteasome inhibitor administration to provide a model of Parkinson's disease in rats and monkeys. Ann. Neurol. 2006, 60:264-268.
14. Landau A.M., Kouassi E., Siegrist-Johnstone R., Desbarats J. Proteasome inhibitor model of Parkinson's disease in mice is confounded by neurotoxicity of the ethanol vehicle. Mov. Disord. 2007, 22:403-407.
15. Li X., Du Y., Fan X., Yang D., Luo G., Le W. c-Jun N-terminal kinase mediates lactacystin-induced dopamine neuron degeneration. J. Neuropathol. Exp. Neurol. 2008, 67:933-944.
16. MacInnes N., Iravani M.M., Perry E., Piggott M., Perry R., Jenner P., Ballard C. Proteasomal abnormalities in cortical Lewy body disease and the impact of proteasomal inhibition within cortical and cholinergic systems. J. Neural Transm. 2008, 115:869-878.
17. Manning-Bog A.B., Reaney S.H., Chou V.P., Johnston L.C., McCormack A.L., Johnston J., Langston J.W., Di Monte D.A. Lack of nigrostriatal pathology in a rat model of proteasome inhibition. Ann. Neurol. 2006, 60:256-260.
18. Mathur B.N., Neely M.D., Dyllick-Brenzinger M., Tandon A., Deutch A.Y. Systemic administration of a proteasome inhibitor does not cause nigrostriatal dopamine degeneration. Brain Res. 2007, 1168:83-89.
19. McNaught K.S., Jenner P. Proteasomal function is impaired in substantia nigra in Parkinson's disease. Neurosci. Lett. 2001, 297:191-194.
20. McNaught K.S., Belizaire R., Jenner P., Olanow C.W., Isacson O. Selective loss of 20S proteasome alpha-subunits in the substantia nigra pars compacta in Parkinson's disease. Neurosci. Lett. 2002, 326:155-158.
21. McNaught K.S., Mytilineou C., Jonbaptiste R., Yabut J., Shashidharan P., Jenner P., Olanow C.W. Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures. J. Neurochem. 2002, 81:301-306.
22. McNaught K.S., Bjorklund L.M., Belizaire R., Isacson O., Jenner P., Olanow C.W. Proteasome inhibition causes nigral degeneration with inclusion bodies in rats. NeuroReport 2002, 13:1437-1441.
23. McNaught K.S., Shashidharan P., Perl D.P., Jenner P., Olanow C.W. Aggresome-related biogenesis of Lewy bodies. Eur. J. Neurosci. 2002, 16:2136-2148.
24. McNaught K.S., Belizaire R., Isacson O., Jenner P., Olanow C.W. Altered proteasomal function in sporadic Parkinson's disease. Exp. Neurol. 2003, 179:38-46.
25. McNaught K.S., Perl D.P., Brownell A.L., Olanow C.W. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann. Neurol. 2004, 56:149-162.
26. Miwa H., Kubo T., Suzuki A., Nishi K., Kondo T. Retrograde dopaminergic neuron degeneration following intrastriatal proteasome inhibition. Neurosci. Lett. 2005, 380:93-98.
27. Nandhagopal R., Kuramoto L., Schulzer M., Mak E., Cragg J., Lee C.S., McKenzie J., McCormick S., Samii A., Troiano A., Ruth T.J., Sossi V., de la Fuente-Fernandez R., Calne D.B., Stoessl A.J. Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study. Brain 2009, 132:2970-2979.
28. Niu C., Mei J., Pan Q., Fu X. Nigral degeneration with inclusion body formation and behavioral changes in rats after proteasomal inhibition. Stereotact. Funct. Neurosurg. 2009, 87:69-81.
29. Olanow C.W., McNaught K.S. Ubiquitin-proteasome system and Parkinson's disease. Mov. Disord. 2006, 21:1806-1823.
30. Pan T., Kondo S., Le W., Jankovic J. The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease. Brain 2008, 131:1969-1978.
31. Pasquali L., Ruggieri S., Murri L., Paparelli A., Fornai F. Does autophagy worsen or improve the survival of dopaminergic neurons?. Parkinsonism Relat. Disord. 2009, 15(Suppl. 4):S24-S27.
32. Poewe W. Non-motor symptoms in Parkinson's disease. Eur. J. Neurol. 2008, 15(Suppl. 1):14-20.
33. Rideout H.J., Lang-Rollin I.C., Savalle M., Stefanis L. Dopaminergic neurons in rat ventral midbrain cultures undergo selective apoptosis and form inclusions, but do not up-regulate iHSP70, following proteasomal inhibition. J. Neurochem. 2005, 93:1304-1313.
34. Rubinsztein D.C. The roles of intracellular protein-degradation pathways in neurodegeneration. Nature 2006, 443:780-786.
35. Schallert T., Woodlee M. Orienting and placing. The Behavior of the Laboratory Rat: A Handbook with Tests 2005, 129-140. Oxford University Press, New York. I. Wishaw, B. Kolb (Eds.).
36. Schapira A.H., Cleeter M.W., Muddle J.R., Workman J.M., Cooper J.M., King R.H. Proteasomal inhibition causes loss of nigral tyrosine hydroxylase neurons. Ann. Neurol. 2006, 60:253-255.
37. Sossi V., Holden J.E., Topping G.J., Camborde M.L., Kornelsen R.A., McCormick S.E., Greene J., Studenov A.R., Ruth T.J., Doudet D.J. In vivo measurement of density and affinity of the monoamine vesicular transporter in a unilateral 6-hydroxydopamine rat model of PD. J. Cereb. Blood Flow Metab. 2007, 27:1407-1415.
38. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997, 388:839-840.
39. Strome E.M., Cepeda I.L., Sossi V., Doudet D.J. Evaluation of the integrity of the dopamine system in a rodent model of Parkinson's disease: small animal positron emission tomography compared to behavioral assessment and autoradiography. Mol. Imaging Biol. 2006, 8:292-299.
40. Sun F., Anantharam V., Zhang D., Latchoumycandane C., Kanthasamy A., Kanthasamy A.G. Proteasome inhibitor MG-132 induces dopaminergic degeneration in cell culture and animal models. Neurotoxicology 2006, 27:807-815.
41. Vernon A.C., Johansson S.M., Modo M.M. Non-invasive evaluation of nigrostriatal neuropathology in a proteasome inhibitor rodent model of Parkinson's disease. BMC Neurosci. 2010, 11:1.
42. West M.J. New stereological methods for counting neurons. Neurobiol. Aging 1993, 14:275-285.
43. Williams R.W., Rakic P. Three-dimensional counting: an accurate and direct method to estimate numbers of cells in sectioned material. J. Comp. Neurol. 1988, 278:344-352.
44. Wu J., Yu W., Chen Y., Su Y., Ding Z., Ren H., Jiang Y., Wang J. Intrastriatal transplantation of GDNF-engineered BMSCs and its neuroprotection in lactacystin-induced Parkinsonian rat model. Neurochem. Res. 2010, 35:495-502.
45. Zeng B.Y., Bukhatwa S., Hikima A., Rose S., Jenner P. Reproducible nigral cell loss after systemic proteasomal inhibitor administration to rats. Ann. Neurol. 2006, 60:248-252.
46. Zhu W., Xie W., Pan T., Xu P., Fridkin M., Zheng H., Jankovic J., Youdim M.B., Le W. Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators. FASEB J. 2007, 21:3835-3844.